These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39108079)

  • 1. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
    Tamma PD; Heil EL; Justo JA; Mathers AJ; Satlin MJ; Bonomo RA
    Clin Infect Dis; 2024 Aug; ():. PubMed ID: 39108079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2023 Jul; ():. PubMed ID: 37463564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2022 Jul; 74(12):2089-2114. PubMed ID: 34864936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2022 Aug; 75(2):187-212. PubMed ID: 35439291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2021 Apr; 72(7):e169-e183. PubMed ID: 33106864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
    Tamma PD; Aitken SL; Bonomo RA; Mathers AJ; van Duin D; Clancy CJ
    Clin Infect Dis; 2021 Apr; 72(7):1109-1116. PubMed ID: 33830222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Meschiari M; Asquier-Khati A; Tiseo G; Luque-Paz D; Murri R; Boutoille D; Falcone M; Mussini C; Tattevin P;
    Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery.
    Righi E; Mutters NT; Guirao X; Del Toro MD; Eckmann C; Friedrich AW; Giannella M; Kluytmans J; Presterl E; Christaki E; Cross ELA; Visentin A; Sganga G; Tsioutis C; Tacconelli E
    Clin Microbiol Infect; 2023 Apr; 29(4):463-479. PubMed ID: 36566836
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Shortridge D; Streit JM; Mendes R; Castanheira M
    Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment guidelines for multidrug-resistant Gram-negative microorganisms.
    Cantón R; Ruiz-Garbajosa P
    Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):46-51. PubMed ID: 37997871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.
    Walker MK; Diao G; Warner S; Babiker A; Neupane M; Strich JR; Yek C; Kadri SS;
    Lancet Infect Dis; 2024 Aug; 24(8):856-867. PubMed ID: 38679036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022.
    Wise MG; Karlowsky JA; Mohamed N; Hermsen ED; Kamat S; Townsend A; Brink A; Soriano A; Paterson DL; Moore LSP; Sahm DF
    J Glob Antimicrob Resist; 2024 Jun; 37():168-175. PubMed ID: 38608936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
    Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
    Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria.
    Pintado V; Ruiz-Garbajosa P; Aguilera-Alonso D; Baquero-Artigao F; Bou G; Cantón R; Grau S; Gutiérrez-Gutiérrez B; Larrosa N; Machuca I; Martínez Martínez L; Montero MM; Morte-Romea E; Oliver A; Paño-Pardo JR; Sorlí L
    Enferm Infecc Microbiol Clin (Engl Ed); 2023; 41(6):360-370. PubMed ID: 36522272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant
    Shropshire WC; Konovalova A; McDaneld P; Gohel M; Strope B; Sahasrabhojane P; Tran CN; Greenberg D; Kim J; Zhan X; Aitken S; Bhatti M; Savidge TC; Treangen TJ; Hanson BM; Arias CA; Shelburne SA
    mSystems; 2022 Oct; 7(5):e0047622. PubMed ID: 36036505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and clinical epidemiology of carbapenem resistant
    Baleivanualala SC; Matanitobua S; Soqo V; Smita S; Limaono J; Sharma SC; Devi SV; Boseiwaqa LV; Vera N; Kumar S; Lalibuli A; Mailulu J; Wilson D; Samisoni Y; Crump JA; Ussher JE
    Lancet Reg Health West Pac; 2024 Jun; 47():101095. PubMed ID: 38867891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial Epidemiology and Antimicrobial Resistance Profiles in Children Reported by the ISPED Program in China, 2016 to 2020.
    Fu P; Xu H; Jing C; Deng J; Wang H; Hua C; Chen Y; Chen X; Zhang T; Zhang H; Chen Y; Yang J; Lin A; Wang S; Cao Q; Wang X; Deng H; Cao S; Hao J; Gao W; Huang Y; Yu H; Wang C
    Microbiol Spectr; 2021 Dec; 9(3):e0028321. PubMed ID: 34730410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016-2020 Compared to 2011-2015: Results From the ATLAS Surveillance Study.
    Yang Q; Kamat S; Mohamed N; Valdez RR; Lin S; Su M; Quintana A; Kiratisin P; Rodríguez-Zulueta AP; Brink A
    J Pediatric Infect Dis Soc; 2023 Aug; 12(8):459-470. PubMed ID: 37643742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.